Inotuzumab ozogamicin and Insulin glargine and lixisenatide Subcutaneous
Determining the interaction of Inotuzumab ozogamicin and Insulin glargine and lixisenatide Subcutaneous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: inotuzumab ozogamicin
Brand name: Besponsa
Synonyms: Inotuzumab Ozogamicin
Generic Name: insulin glargine / lixisenatide
Brand name: Soliqua 100/33
Synonyms: Insulin glargine and lixisenatide (Subcutaneous)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Inotuzumab ozogamicin-Insulin glargine, recombinant Subcutaneous
- Inotuzumab ozogamicin-Insulin glulisine
- Inotuzumab ozogamicin-Insulin Glulisine (Cartridges and Pens)
- Inotuzumab ozogamicin-Insulin Glulisine (Vials)
- Inotuzumab ozogamicin-Insulin glulisine Subcutaneous
- Inotuzumab ozogamicin-Insulin human inhaled Inhalation
- Insulin glargine and lixisenatide Subcutaneous-Inotuzumab ozogamicin Intravenous
- Insulin glargine and lixisenatide Subcutaneous-Inova
- Insulin glargine and lixisenatide Subcutaneous-Inova 4/1 topical
- Insulin glargine and lixisenatide Subcutaneous-Inova 8/2 topical
- Insulin glargine and lixisenatide Subcutaneous-Inova ACT
- Insulin glargine and lixisenatide Subcutaneous-Inrebic